Italia markets close in 2 hours 57 minutes
FTSE MIB
34.394,53 -275,53 (-0,79%) Dow Jones
38.571,03 -115,27 (-0,30%) Nasdaq
16.828,67 +93,67 (+0,56%) Nikkei 225
38.837,46 -85,54 (-0,22%) Petrolio
72,80 -1,42 (-1,91%) Bitcoin EUR
63.504,74 -337,90 (-0,53%)
NVCR Sep 2024 17.500 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:44AM EDT. Mercato aperto.
| Chiusura precedente | 2,8000 |
| Aperto | 4,5000 |
| Denaro | 0,0000 |
| Domanda | 0,0000 |
| Prezzo d'esercizio | 17,50 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 2,7500 - 2,8000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 97 |
GlobeNewswireZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
© 2024 Yahoo. Tutti i diritti riservati.